Related Experiment Video

Updated: Nov 25, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.8K

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes

Yangzhi Qi1, Baohui Liu1, Qian Sun1

  • 1Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.

Frontiers in Immunology
|December 17, 2020
PubMed

Insights

Glioma immunotherapy faces challenges due to the tumor microenvironment and resistance. Understanding brain immunity and developing better biomarkers are crucial for effective glioma treatments.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Therapy

Background:

  • Glioma is a highly malignant brain tumor with poor survival rates.
  • Immune checkpoint blockade shows promise but faces significant hurdles in glioma treatment.
  • The "cold phenotype" and resistance mechanisms limit current immunotherapy efficacy in glioma patients.

Purpose of the Study:

  • To highlight the challenges in applying immune checkpoint blockade for glioma.
  • To emphasize the need for understanding the brain's tumor microenvironment and immune status.
  • To identify strategies for improving glioma immunotherapy outcomes.

Main Methods:

  • Review of current literature on glioma immunology and immunotherapy.
  • Analysis of factors contributing to resistance in glioma treatment.
  • Discussion of potential biomarkers and combination strategies.

Main Results:

  • Glioma's "cold phenotype" and intrinsic/acquired resistance mechanisms impede immunotherapy.
  • The unique immunological status of the brain presents specific challenges.
  • Current immunotherapy approaches require significant advancements for clinical success.

Conclusions:

  • A deeper understanding of the glioma tumor microenvironment is essential.
  • Developing sensitive biomarkers for immune response monitoring is critical.
  • Combining multiple immunotherapy strategies may overcome resistance and improve patient outcomes.
Keywords:
brain immunologyglioma microenvironmentimmune checkpoint blockadeimmune-response monitoring biomarkerimmunotherapy resistance

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
884
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K